Dr. Steven M. Paul, also known as Steve, M.D. has been the Chief Executive Officer of Voyager Therapeutics, Inc. since September 3, 2014 and has been its President since September 2014. Dr. Paul serves as a Venture Partner at Third Rock Ventures, LLC. He cofounded Tal Medical, Inc. in 2010 and serves as SAB Chair. He is the Founding Chief Executive Officer at Tal Medical. Dr. Paul is a world renowned psychiatrist, neuroscientist and drug developer. He has more than 20 years of management experience in the pharmaceutical and biotechnology industries and 37 years of scientific research experience. He has more than 35 years of neuroscience expertise. Dr. Paul joined Third Rock Ventures on October 5, 2010 and is a Senior Advisor to it and participates in the ideation and development of potential new companies. He is also the Professor of Neurology, Neuroscience, Psychiatry and Pharmacology at Weill Cornell Medical College of Cornell University. He serves as a Scientific Advisor at Excalibur Fund Managers Limited. He served as Advisor of PureTech Ventures. He founded Sage Therapeutics, Inc. in 2011 and served as its Interim Chief Scientific Officer and Founding Advisor. Dr. Paul served as Interim President of R&D of Voyager Therapeutics, Inc. from June 2013 to September 3, 2014. Dr. Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles and was responsible for its overall research and development efforts - helping to expand Lilly's R&D efforts in oncology and biotechnology - resulting in a pipeline of approximately 70 new molecular entities. During Steve’s time at Lilly, Lilly launched some of the most successful psychiatric drugs of all time including the current market leading antidepressant, Cymbalta, which was developed under his direction. Dr. Paul was the Executive Vice President of Science and Technology at Eli Lilly and Company from July 2003 to February 28, 2010. He was the President of Lilly Research Laboratories of Eli Lilly and Company from May 16, 2003 to February 28, 2010 and Vice President since 1998. Dr. Paul joined Eli Lilly and Company in 1993 as the Vice President of Central Nervous System Discovery and Decision Phase Medical Research group in it and was the Group Vice President of Therapeutic Area Discovery Research and Clinical Investigation from 1996 to 2003. He was also the Vice President of Neuroscience Discovery Research at the company, helping to expand Lilly's R&D efforts in oncology and biotechnology - resulting in a pipeline of approximately 70 new molecular entities. He was the Scientific Director of the Intramural Research Program at National Institute of Mental Health and as the Chief of its Clinical Neuroscience branch. He was the President in Psychiatry and an Instructor in the department of Psychiatry at University of Chicago’s Pritzker School of Medicine. Dr. Paul was a Medical Director in the Commissioned Corps of the United States Public Health Service. He serves as the Chairman of Karuna Pharmaceuticals Inc. He serves as a Director of Sigma-Aldrich Company Limited. He serves as a Director of the Appel Alzheimer's Disease Research Institute. Dr. Paul serves as an Independent Director of Sigma-Aldrich Corporation since November 2006 and ImClone Systems LLC since November 21, 2008. He has been a Director of Sage Therapeutics, Inc since September 2011. Dr. Paul has been a Director for Alnylam Pharmaceuticals, Inc. since September 2010 and Seaside Therapeutics LLC since July 2010. He serves as a Director at Tal Medical, Inc. He serves as Scientific Advisory Board Member at Tal Medical. He has been a Director of Voyager Therapeutics, Inc. since September 2014. He serves as a Director of DemeRx, Inc, the Lilly Foundation, the Foundation For The National Institutes Of Health Inc., Butler University and the Indianapolis Zoological Society. He served as a Member of Scientific Advisory Board of PsychoGenics Inc. He served as a Director of Constellation Pharmaceuticals, Inc., since February 1, 2011. He served as a Member of Scientific Advisory Board at Cerecor, Inc. He serves as a Member of Science Board at the FDA. Dr. Paul serves as Member of Science Advisory Board of The Mind Research Network. He serves as a member of the Scientific Advisory Board of the Allen Institute for Brain Sciences and the Institute on Aging at the University of Pennsylvania’s School of Medicine. Dr. Paul was the Director of Helen & Robert Appel Institute for Alzheimer's Research at Weill Cornell Medical College, Inc. Dr. Paul served as a Director at BioCrossroads. He served as a Trustee of The Mind Research Network. He was appointed by the Secretary of the Department of Health and Human Services. He is a Grant Reviewer for several National Institute of Health committees. Dr. Paul serves on the IOM’s Board on Health Sciences Policy. Dr. Paul is on the Editorial Boards of numerous scientific journals. Dr. Paul has authored or co-authored more than 500 papers and invited book chapters. He holds eight patents on inventions made at Lilly and NIH. He was listed as one of the most highly cited Neuroscientists in the world from 1980 to 2000 by Institute of Scientific Information. Dr. Paul was awarded a research fellowship in the Pharmacology Research Associate Training Program of the National Institute of General Medical Science to work with Dr. Julius Axelrod. He completed an Internship in Neurology at Charity Hospital in New Orleans. Dr. Paul is Board certified by the American Board of Psychiatry and Neurology. He is a Fellow of the American Association for the Advancement of Science. Dr. Paul is the recipient of many honors and awards including The Distinguished Service Medal of the USPHS and the Chief Scientific Officer of the Year Award. He is a member of the Institute of Medicine of the National Academy of Sciences. He received a Doctor of Medicine and a MSc in Anatomy and Neuroanatomy from Tulane University School of Medicine in 1975 and a B.A. in Biology and Psychology from Tulane University in 1972.  

 pathology